hotspot -WSS

hotspot

author：explore 2025-10-02 20:47:35 - browse：927

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

leisure time

WSS

Free medical tuition alone isn't enough to close gaps in primary care

AI can’t replace a physician’s gut feeling

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Doctors find melanoma drugs effective against rare brain cancer

Ripples from Flovent's discontinuation is killing children with asthma

WHO calls for emergency meeting on new China virus, as cases spread

focus

hotspot

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Wildfire smoke exposes gaps in outdoor worker protections

STAT series 'Denied by AI' wins major journalism prizes

How to save PrEP access — and even expand it

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Moonlake's readout produced a cash windfall. Risks remain

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Alkermes shareholders re

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

entertainment

Custom gene therapy hints at new path for rare disease treatments

WHO calls for emergency meeting on new China virus, as cases spread

Google and Epic fight stronger regulation of AI in health care

Cherokee Nation medical school graduates its first class

Startup Neumora takes a novel depression drug to Phase 3

As digital health tech proliferates, a new institute aims to cut through hype

entertainment

focus

leisure time

hotspot